Nile Therapeutics (NLTX) Appoints Dr.Frank Litvack to Board Of Directors
By Ben Zinga
September 25, 2009 7:28 AM
September 25, 2009 7:28 AM
Symbols: NLTX
Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, announced the appointment of Frank Litvack, M.D., to its Board of Directors
Dr. Litvack is a seasoned veteran of the cardiovascular healthcare space, with over 25 years of academic and industry experience. Dr. Litvack is a Professor at the David Geffen School of Medicine, University of California, Los Angeles.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
